Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Neuropharmacology is Scopus-indexed (Q1, CiteScore 8.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ltd.
Checked against the index lists dated .
ISSN 0028-3908Verify ISSN ↗1873-7064Verify ISSN ↗
Publisher: Elsevier Ltd
Cost to publish: About US$4,300 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 62 / 328 | 81st | Q1 |
| Cellular and Molecular Neuroscience | 27 / 102 | 74th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1962–present, best quartile Q1, CiteScore 8.1.
Neuropharmacology is Q1 in Pharmacology (rank 62 of 328) and Q2 in Cellular and Molecular Neuroscience (rank 27 of 102), by CiteScore 2025.
Neuropharmacology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.1, which places it in quartile Q1 at the 81st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.568, quartile Q1, with an H-index of 206.
The publisher lists an article processing charge of about US$4,300 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Neuropharmacology is published by Elsevier Ltd. Its print ISSN is 0028-3908 and its online ISSN is 1873-7064.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Neuropharmacology has an h-index of 247 and a 2-year mean of 4.06 citations per paper (OpenAlex). Its Scopus CiteScore is 8.1, quartile Q1. On 2-year citations it ranks #71 of 319 Scopus journals in Pharmacology.
Neuropharmacology published 396 papers in 2025; its busiest recent year was 2017 with 481. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (27.7%), United States (24.5%) and Spain (5.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 13 retracted papers are recorded (0.9 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.